# CorMedix share price today (CorMedix Inc., CRMD)

> CorMedix Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CRMD · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/crmd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $5.66 (−47.4% in a year)
- P/E: 2.7× (lower than 98% of the last 1 year)
- Revenue (Jun 2026): $102 M (+156.5% on a year ago)
- Profit (Jun 2026): $25.8 M (+31.0% on a year ago)
- Operating margin: 42.1% (−7.1 points on a year ago)
- ROE: 40%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the CorMedix share price today? CorMedix Inc.'s share price was $5.66 at the close on 4 November 2026. It has been falling for 2 weeks. That is 26.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $13, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 11 weeks running. Over the last 10 years the share price moved −37% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 21 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does CorMedix pay? CorMedix Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is CorMedix on? CorMedix is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is CorMedix profitable? CorMedix Inc. earned $25.8 M of net profit in the Jun 2026 quarter, +31.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $162 M. That is 25.3% of the quarter's revenue. The same quarter a year earlier earned $19.7 M. 5 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed +156.5% on a year earlier and the margin moved −7.1 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +38.3% and revenue +376.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does CorMedix make, and is it growing? CorMedix Inc. reported $102 M of revenue in the Jun 2026 quarter, +156.5% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 535.6% a year on average. The last full year, FY25, came in at $312 M. The last four reported quarters add to $462 M. FY25 revenue was $312 M, +617.0% on the year before. Recent pace: the last four quarters grew +376.2% on average, against 535.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +280.5%, against +2,213.0% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does CorMedix keep? CorMedix Inc.'s operating margin was 42.1% in the Jun 2026 quarter, 7.1 percentage points lower than the same quarter a year ago. Across 4 years it has been between −47,113.8% and 51.4%. The latest quarter is within that range. Why the margin moved: operating margin changed −7.1 percentage points on the year while gross margin changed −9.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is CorMedix's profit turning into cash? CorMedix Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $175 M of operating cash against $162 M of profit. After $2.3 M of spending on assets, $173 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does CorMedix's cash go? CorMedix Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.6 M on assets over the last 3 years. Averaged over those years that is 0.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.6 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is CorMedix's P/E ratio, and how does it compare with its own history? CorMedix Inc.'s P/E is 2.7×, about the lowest it has ever been. Its usual P/E (the middle reading) is 4.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the CorMedix business getting better or worse? CorMedix Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does CorMedix earn on its capital? CorMedix Inc. earned a ROE of 40% in FY25. That is up from a low of −54% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −2,428%, a number that says nothing useful about the business. It comes from a 52.0% net margin and 0.38× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 52.0% net margin × 0.38× asset turnover × 2.04× leverage (assets divided by equity) ≈ 40.3% on equity. The margin does most of the work; borrowing is a big part of it. ## Does CorMedix have too much debt? CorMedix Inc. has total debt of $147 M against shareholder equity of $461 M as of Jun 2026, so its debt is 0.32× its equity. Year by year, that ratio went from 0.01 in FY21 to 0.37 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the CorMedix shareholding pattern? 22.3% of CorMedix Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 14.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is CorMedix from balance-sheet trouble? For CorMedix Inc., the Z-score is 2.57. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.57 is in the grey area, neither clearly safe nor clearly in trouble. ## How does CorMedix rank in its industry? There is no score against its industry: CorMedix Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is CorMedix compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to CorMedix in size? CorMedix is the 150th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: MiMedx Group, Inc., Phathom Pharmaceuticals, Inc. and Oculis Holding AG. Just below it: Prothena Corporation plc, Prelude Therapeutics Incorporated and Editas Medicine, Inc. ### Biotechnology companies close in size

1. [MiMedx Group, Inc.](https://www.sectoralpha.in/us/stocks/mdxg) $467 million
2. [Phathom Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/phat) $451 million
3. [Oculis Holding AG](https://www.sectoralpha.in/us/stocks/ocs) $449 million
4. CorMedix Inc. $441 million
5. [Prothena Corporation plc](https://www.sectoralpha.in/us/stocks/prta) $431 million
6. [Prelude Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/prld) $420 million
7. [Editas Medicine, Inc.](https://www.sectoralpha.in/us/stocks/edit) $418 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Value Line, Inc.](https://www.sectoralpha.in/us/stocks/valu) $434 million · Financial Data & Stock Exchanges
2. [BrightSpire Capital, Inc.](https://www.sectoralpha.in/us/stocks/brsp) $434 million · REIT - Mortgage
3. CorMedix Inc. $433 million
4. [Barnes & Noble Education, Inc.](https://www.sectoralpha.in/us/stocks/bned) $433 million · Specialty Retail
5. [Gladstone Capital Corporation](https://www.sectoralpha.in/us/stocks/glad) $433 million · Asset Management

## What else do people ask about CorMedix? ### What were CorMedix's latest quarterly results? CorMedix Inc. reported revenue of $102 M and net profit of $25.8 M for the Jun 2026 quarter. Revenue rose 156.5% and profit rose 31.0% compared with a year earlier. Earnings per share were $0.29. The operating margin was 42.1%, 7.1 percentage points lower than a year earlier (as of 4 November 2026). ### What is CorMedix's market cap? CorMedix Inc.'s market capitalisation is $441 M at a stock price of $5.66. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### What is CorMedix's P/E ratio? CorMedix Inc.'s P/E is 2.7×, higher than 2% of its own last 2 years. Its usual level (the middle reading) is 4.1×. This compares the price with the company's own past; it is not a view on what the shares are worth (as of 4 November 2026). ### How is CorMedix valued against its own history? Against its own history, CorMedix Inc.'s valuation is low: its P/E of 2.7× has been lower only 2% of the time in 2 years (usual level 4.1×). This compares the price with the company's own past; it is not a view on what the shares are worth or where the price goes next (as of 4 November 2026). ### How is CorMedix performing? CorMedix Inc.'s share price has been falling for 2 weeks. In its latest quarter, revenue rose 156.5% and profit rose 31.0% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 11 weeks running (as of 4 November 2026). ### Will CorMedix's stock price go up? This page does not forecast CorMedix Inc.'s stock price. What it shows instead: the stock price is $5.66, and it has been falling for 2 weeks. Its P/E of 2.7× is higher than 2% of its own last 2 years (as of 4 November 2026). ### Where is CorMedix in its business cycle? CorMedix Inc.'s FY25 operating margin was 51.4%, against a 4-year range of −47,113.8% to 51.4%: the middle of its own range, neither a peak nor a low. The latest quarter was 42.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the CorMedix story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is CorMedix a stock worth studying right now? What the numbers show: CorMedix Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.